3 Health Services Stocks Pushing The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 125 points (0.7%) at 17,965 as of Friday, May 1, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,606 issues advancing vs. 1,375 declining with 147 unchanged.

The Health Services industry currently sits down 0.4% versus the S&P 500, which is up 0.6%. Top gainers within the industry include UnitedHealth Group ( UNH), up 1.8%, St Jude Medical ( STJ), up 1.6%, CVS Health ( CVS), up 1.1%, Medtronic ( MDT), up 1.1% and Anthem ( ANTM), up 1.0%. A company within the industry that fell today was Boston Scientific ( BSX), up 1.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Smith & Nephew ( SNN) is one of the companies pushing the Health Services industry higher today. As of noon trading, Smith & Nephew is up $0.55 (1.6%) to $34.44 on average volume. Thus far, 268,321 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 514,100 shares. The stock has ranged in price between $34.40-$34.75 after having opened the day at $34.48 as compared to the previous trading day's close of $33.89.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $16.5 billion and is part of the health care sector. Shares are down 5.6% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates Smith & Nephew a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Smith & Nephew Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, DaVita HealthCare Partners ( DVA) is up $0.93 (1.1%) to $82.03 on light volume. Thus far, 422,891 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $81.61-$82.37 after having opened the day at $81.69 as compared to the previous trading day's close of $81.10.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates in two divisions, Kidney Care and HealthCare Partners. DaVita HealthCare Partners has a market cap of $17.8 billion and is part of the health care sector. Shares are up 9.1% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts who rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is up $0.79 (0.6%) to $126.47 on average volume. Thus far, 798,630 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $126.28-$127.44 after having opened the day at $126.50 as compared to the previous trading day's close of $125.68.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. Thermo Fisher Scientific has a market cap of $50.6 billion and is part of the health care sector. Shares are up 1.5% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts who rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Thermo Fisher Scientific Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

If you liked this article you might like

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Smith & Nephew Surges to Record High on Reports of Elliott Stake

Smith & Nephew Surges to Record High on Reports of Elliott Stake

Cramer: Don't Fear the Activist

Cramer: Don't Fear the Activist

European Stocks Rise but London Blue Chips Slip on Stronger Pound

European Stocks Rise but London Blue Chips Slip on Stronger Pound

Take Advantage of U.K. Budget to Bag Some Bargains

Take Advantage of U.K. Budget to Bag Some Bargains